liver damage
Conditions
Interventions
Ruanjian Qingmai group, paracetamol group, phenacetin group and magnesium isoglycyrrhizinate group:Ruanjian Qingmai group, paracetamol group, phenacetin group and magnesium isoglycyrrhizinate
Sponsors
Institute of Vascular Diseases, Hospital of Integrated Traditional Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Male or female 2. No age limit; No history of allergy to antipyretic analgesics and licorice preparations, gastric ulcer, bleeding disease, blood system disease, liver and kidney insufficiency, cardiovascular and cerebrovascular disease; 3.No history of allergy to antipyretic analgesics and licorice preparations, gastric ulcer, bleeding disease, blood system disease, liver and kidney insufficiency, cardiovascular and cerebrovascular disease; 4 Healthy volunteers.
Exclusion criteria
Exclusion criteria: 1. Acute cardiovascular and cerebral vascular diseases such as stroke and myocardial infarction; 2.patients with severe respiratory diseases, severe cervical and lumbar lesions, severe liver and kidney damage and malignant tumors; 3 with hepatitis, tuberculosis, AIDS and other infectious diseases; 4.Patients with organic mental disorders or those who could not cooperate with conventional treatment were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine transaminase;The levels of APAP, APAP-Gly, APAP-Sulf, APAP-Cys and NAC in blood and urine were detected after administration; | — |
Countries
China
Contacts
Public Contactjiachenglin
Institute of Vascular Diseases, Hospital of Integrated Traditional Chinese and Western Medicine
Outcome results
None listed